Welcome to the HOPE for Harvey Foundation for DLG4
Helping Overcome PSD-95 Errors for the DLG4 Community
Welcome to the HOPE for Harvey Foundation for DLG4
Helping Overcome PSD-95 Errors for the DLG4 Community
Helping Overcome PSD-95 Errors for the DLG4 Community
Helping Overcome PSD-95 Errors for the DLG4 Community

We have finally DONE it! Grann Pharmaceuticals on behalf of HOPE for Harvey filed the first application to the FDA for a Pre-Investigational New Drug on January 28, 2026 for the first ever targeted treatment of DLG4. This mRNA-based treatment will be delivered via regular infusions of Lipid Nano Particles (LNPs), which will send good copies of DLG4 into the body, passing the blood brain barrier, and hopefully expressing healthy copies of DLG4 protein. This LNP mRNA treatment is showing amazing and safe results in another active clinical trial in just 18 months. Right now we are trying ot raise another $100,000 by the end of February 2026, and we have a $25,000 matching pledge right now, which will help pay for our safety studies this spring 2026. Help make that $25,000 into $50,000 or more.
We hope to submit our final IND FDA application by early summer 2026 with hopes to start our first clinical trial for an Investigational New DLG4 Drug in Austin, TX by the end of summer 2026! We hope to quickly move into expanded access and start adding other patients by fall 2026.
You can help make this possible by donating today!
To further research and create translational medicine and treatment options that create a better quality of life for DLG4 patients.
In the long-term we hope our efforts will go beyond DLG4 and help increase research and legislation in this field for early detection and treatment of all rare genetic disorders.
Americans affected by rare genetic diseases like DLG4
identified
genetic disorders
of disorders have an FDA-approved treatment
In March of 2020, we gave birth to our second child, Harvey. At 18-months, he was diagnosed with DLG4-related Synaptopathy. Harvey is now 5-years-old, and struggles with seizures, independent mobility and cannot speak or feed himself. He has difficulty learning due to a random, single letter mutation on the DLG4 gene
We hope to be in clinical trials for a Lipid Nano Particle mRNA treatment by summer 2026!
Help make that possible for Harvey and DLG4!
There's still hope. Donate today!
100% of donations go straight to researchers
Powered by
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.